Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • Mifepristone (RU486): A Progesterone Receptor Antagonist ...

    2025-12-05

    Mifepristone (RU486): A Progesterone Receptor Antagonist for Oncology & Reproductive Research

    Executive Summary: Mifepristone (RU486) is a high-affinity progesterone receptor antagonist, widely implemented in reproductive biology and oncology research. It inhibits progesterone receptor signaling, resulting in dose-dependent suppression of ovarian cancer cell proliferation (IC50: 6.25–6.91 μmol/L) (APExBIO, B1511). The compound reduces uterine fibroid size and blocks progesterone-induced acrosome reaction in human sperm (Li et al., 2018). Mifepristone also demonstrates anti-proliferative activity across diverse carcinoma cell lines and is a benchmark for glucocorticoid and progesterone receptor antagonism assays. It is supplied as a solid, soluble in DMSO/ethanol, and should be stored at -20°C. These properties establish Mifepristone as a versatile, reliable reagent for advanced cellular and molecular assays in hormone signaling and cancer biology.

    Biological Rationale

    Mifepristone (RU486) is classified as a steroidal antiprogestogen. Its primary action involves competitive antagonism of the progesterone receptor (PR), a nuclear hormone receptor critical for reproductive tissue differentiation and homeostasis (Li et al., 2018). In reproductive biology, PR signaling regulates menstrual cycle progression, endometrial receptivity, and early pregnancy maintenance. Aberrant progesterone signaling is implicated in pathologies such as uterine fibroids and certain reproductive system cancers. In oncology, PR and glucocorticoid receptor pathways intersect with proliferative and apoptotic signaling, influencing tumor growth and therapeutic response. Mifepristone’s antagonism of these pathways allows for targeted investigation of hormone-driven cellular processes. Its cell-permeability and stability under laboratory conditions enable robust mechanistic studies, particularly in models of ovarian, endometrial, breast, prostate, and gastric adenocarcinoma.

    Mechanism of Action of Mifepristone (RU486)

    Mifepristone acts by binding with high affinity to the progesterone receptor ligand-binding domain, thereby displacing endogenous progesterone and blocking receptor-mediated transcriptional activation (APExBIO, B1511). This antagonism results in downregulation of progesterone-responsive gene expression. Mifepristone also exhibits partial antagonism of the glucocorticoid receptor, but with lower potency. In cellular models, Mifepristone induces cell cycle arrest by decreasing expression of S phase (cyclin A) and M phase (cyclin B1) cyclins in ovarian cancer cells, correlating with reduced proliferation rates. In sperm, it blocks the progesterone-induced acrosome reaction, hyperactivation, and intracellular calcium influx, providing a mechanistic basis for its contraceptive effect. Mifepristone’s dose-dependent effects on tumor cell lines are linked to its modulation of steroid hormone receptor signaling, apoptosis, and cell cycle checkpoints.

    Evidence & Benchmarks

    • Mifepristone inhibits ovarian cancer cell growth with IC50 values of 6.25 μmol/L (SK-OV-3) and 6.91 μmol/L (OV2008) in vitro (APExBIO, B1511).
    • Mifepristone reduces uterine fibroid size and inhibits meningioma cell proliferation in both in vitro and in vivo models (Li et al., 2018).
    • It demonstrates anti-proliferative effects on endometrial, breast, prostate, and gastric adenocarcinoma cell lines (Li et al., 2018).
    • Mifepristone inhibits the progesterone-induced acrosome reaction in human sperm, interfering with sperm function and fertilization (Li et al., 2018, Table 2).
    • In T47D and A549 cell lines, Mifepristone serves as a positive control for glucocorticoid and progesterone receptor antagonism assays (APExBIO, B1511).
    • Benchmarked protocols recommend solubility at ≥21.48 mg/mL in DMSO or ethanol (with gentle warming), but note insolubility in water (APExBIO, B1511).

    This article extends prior overviews such as "Mifepristone (RU486): Data-Driven Solutions for Oncology ..." by providing granular evidence benchmarks, and clarifies the mechanistic basis outlined in "Mifepristone (RU486): Mechanistic Insights and Strategic ..." with new quantitative data.

    Applications, Limits & Misconceptions

    Mifepristone’s validated roles include:

    • In vitro studies of progesterone receptor signaling and hormone-driven tumorigenesis.
    • Experimental models for uterine fibroid reduction and endometrial biology.
    • Sperm function assays evaluating acrosome reaction and calcium flux.
    • Cancer cell line studies (including ovarian, breast, prostate, endometrial, and gastric adenocarcinoma).
    • Preclinical tumor xenograft models evaluating dose-dependent tumor growth inhibition.

    Common Pitfalls or Misconceptions

    • Mifepristone is not water-soluble; attempts to prepare aqueous stock solutions result in precipitation and variable dosing.
    • It is a broad-spectrum steroid receptor antagonist, but glucocorticoid receptor antagonism requires higher concentrations.
    • Long-term storage of DMSO or ethanol solutions at ambient temperature leads to degradation; -20°C or below is required for stability.
    • Mifepristone’s effects on AR-negative prostate cancer cell lines are limited; its efficacy is context-dependent and should not be generalized to all cancers (Li et al., 2018).
    • Clinical contraceptive and abortifacient applications are distinct from research-grade, in vitro uses of the compound.

    For a comprehensive review of hormone signaling and tumor biology, see "Mifepristone (RU486): Advanced Insights into Progesterone...", which this article updates with new evidence benchmarks.

    Workflow Integration & Parameters

    APExBIO’s Mifepristone (RU486, SKU B1511) is supplied as a solid and should be dissolved in DMSO or ethanol (≥21.48 mg/mL) with gentle warming. Stock solutions can be stored below -20°C for several months but should not be kept in solution long-term. For cell-based assays, standard working concentrations range from 1–20 μmol/L, depending on cell type and experimental endpoint. T47D and A549 cell lines are recommended for glucocorticoid and progesterone receptor antagonism validation. For tumor xenograft models, dose selection should be guided by in vitro IC50 values and pilot tolerability studies. Shipping is performed on blue ice to preserve integrity. For workflow-specific troubleshooting and best practices, consult "Mifepristone (RU486): Data-Driven Solutions for Oncology ...", which complements this article’s evidence-driven focus with lab protocol guidance.

    Conclusion & Outlook

    Mifepristone (RU486) remains a cornerstone tool for dissecting progesterone receptor signaling and evaluating hormone-driven tumorigenesis. Its multi-modal activity, robust solubility, and proven in vitro/in vivo benchmarks make it indispensable for advanced cancer and reproductive biology research. APExBIO’s high-purity formulation (B1511) ensures reproducibility and compatibility across diverse assay platforms. Ongoing studies continue to elucidate its utility in emerging models of hormone receptor signaling complexity and tumor heterogeneity (Li et al., 2018).